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Summary
The treatment landscape for mantle cell lymphoma (MCL) has changed
dramatically in recent years, with findings from clinical trials reporting
improvements in survival. Data on the general patient population are, how-
ever, sparse; and it is unclear whether the effects observed in clinical trials
have translated into the real-world setting. To investigate this, we examined
first-line and relapsed/refractory (RR) disease management in 335 MCL
patients diagnosed between 2004 and 2015 in an established population-
based patient cohort, along with data on demographic, diagnostic and
prognostic factors. Marked treatment and survival changes were observed;
first-line rituximab immunotherapy, for example, increased from 32% to
86% over the 11-year period, and median survival increased from 20 years
among those first treated in 2004–2011 to 35 years among those treated in
2012–2015. Outcomes for RR disease also improved, from 8 months in
2004–2011 to 168 months in 2012–2015, coinciding with the introduction
of agents, such as bendamustine and ibrutinib. Encouragingly, improve-
ments were seen across all ages; 1-year overall survival among patients over
70 years treated for RR disease almost doubled. Our analyses underscore
the importance of monitoring the impact of treatment changes in the real-
world setting.
Keywords: mantle cell lymphoma, international prognostic index, popula-
tion-based, novel agents.
First recognized as an official entity in 1994 (Harris et al,
1994), mantle cell lymphoma (MCL) is a relatively rare B-cell
malignancy characterized by diverse patient pathways and a
generally poor prognosis (Martin et al, 2017). With a median
diagnostic age of around 70 years, MCL occurs 2-3 times
more frequently in men than women (Abrahamsson et al,
2014; Leux et al, 2014; Smith et al, 2015; Vergote et al,
2017); and although a small subset of patients present with
localized/indolent disease that can be treated with radiother-
apy and/or managed by watch and wait (W&W), the major-
ity present with advanced disease that requires chemotherapy
(McKay et al, 2012; Dreyling et al, 2017; National Compre-
hensive Cancer Network, 2017). Unfortunately, however,
even though many patients respond well to first-line treat-
ment, remission is generally short-lived, response to second
and subsequent lines is poor, and survival is lower than most
other lymphoma subtypes (Marcos-Gragera et al, 2011;
Chandran et al, 2012; Smith et al, 2015) with 5-year overall
survival estimates ranging from 30% to 50% in the general
patient population (Marcos-Gragera et al, 2011; Abra-
hamsson et al, 2014; Smith et al, 2015).
The MCL treatment landscape is, however, changing
rapidly as understanding about the biology of the disease
grows and the number of life-prolonging treatments expands
(Colbourn et al, 2016; Rule, 2016; Kahl et al, 2017; Martin
et al, 2017). Encouragingly, based largely on findings from
clinical trials, international guidelines for first-line therapies
are becoming increasingly systematized; dose-intensified
immunochemotherapy regimens followed by autologous stem
cell transplant (ASCT) are now the standard of care for
younger fitter patients, and conventional immunochemother-
apy when intensive regimens are deemed inappropriate
(McKay et al, 2012; Dreyling et al, 2017; Martin et al, 2017;
National Comprehensive Cancer Network, 2017). In
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addition, with the aim of increasing the duration of progres-
sion-free survival (PFS), rituximab maintenance therapy is
currently the agreed standard of care for patients who
respond to first-line treatment (Kluin-Nelemans et al, 2012;
Vidal et al, 2016; Dreyling et al, 2017; Le Gouill et al, 2017;
Martin et al, 2017). Nonetheless, although the general popu-
lation of patients seem to be living longer than they did in
the past, relapse remains unavoidable.
Whilst guidelines are available in the UK for first line ther-
apy, there is no agreed standard of care for the management of
patients with relapsed/refractory (RR) MCL (McKay et al,
2012; Zaja et al, 2014; Atilla et al, 2017; Dreyling et al, 2017;
Martin et al, 2017; National Comprehensive Cancer Network,
2017); options including additional immunochemotherapy, or
treatment with novel targeted agents, such as ibrutinib (Drey-
ling et al, 2016; Wang et al, 2016; Martin et al, 2017). In this
context, while real-world data has linked recent changes in
first-line management to improvements in survival for the
Nordic countries and parts of France (Abrahamsson et al,
2011, 2014; Leux et al, 2014), as well as for RR MCL in Bel-
gium(Epperla et al, 2017), comparable data from other coun-
tries are exceedingly sparse. Such data are, however, required
in order to monitor the impact of therapeutic change at the
population level, and to inform decision-making for clinicians
and regulatory agencies. This is particularly pertinent in rare
diseases like MCL, where the number of patients entering clin-
ical trials is relatively small and findings may not generalize to
the patient population as a whole. To investigate the changing
treatment landscape and impact on outcome in the real-world
setting, we used MCL data from an established UK popula-
tion-based patient cohort – the Haematological Malignancy
Research Network (HMRN; www.hmrn.org).
Methods
Data are from the UK population-based Haematological
Malignancy Research Network (HMRN; www.hmrn.org),
which, with a catchment population of nearly 4 million peo-
ple, has a socio-demographic composition that broadly mir-
rors that of the UK as a whole. Initiated in 2004, full details
of its structure, data collection methods and ethical approvals
have been previously described (Smith et al, 2011, 2015).
Briefly, within HMRN, patient care is provided by 14 hospi-
tals [Teaching (academic) and District (community)], orga-
nized into five multi-disciplinary teams (MDTs); and clinical
practice adheres to national guidelines. Patients requiring an
autologous stem cell transplant are treated/referred to one of
the three hospitals in the Network that deliver this service.
As a matter of policy, all diagnoses across the HMRN region
are made to current WHO diagnostic criteria and coded by
clinical specialists at a single integrated haematopathology
laboratory – the Haematological Malignancy Diagnostic Ser-
vice (www.hmds.info).
HMRN operates with Section 251 support under the NHS
Act 2006, which allows full-treatment, response and outcome
data to be collected on all patients, regardless of consent, as
well as ‘flagging’ for death at the national Medical Research
Information Service (MRIS) and linkage to nationwide infor-
mation on Hospital Episode Statistics (HES). Area-based
population counts are sourced from the Office for National
Statistics. The present report includes all patients with a con-
firmed new diagnosis of mantle cell lymphoma (MCL) either
with evidence of t(11:14) or cyclin D1 (CCND1) overexpres-
sion between 1 September 2004 and 31 August 2015; all of
whom were followed up until 25 March 2017.
Analyses were conducted using standard methods in the
statistical package Stata v14 (https://www.stata.com/stata14/).
Time to event analyses, namely Kaplan-Meier and Cox pro-
portional hazard regression, were used to estimate overall
survival (OS); the log rank test was used to compare survival
curves. OS was assessed by demographic, prognostic and
clinical characteristics including the simplified MCL Interna-
tional Prognostic Index (MIPI) score, which was calculated
from its components (Hoster et al, 2008) [i.e. age at diagno-
sis, lactose dehydrogenase (LDH) levels, white blood cell
(WBC) count and performance status] and by the cell prolif-
eration marker Ki67 (Klapper et al, 2009) measured from
time of diagnosis. Relative survival (RS) was also estimated,
this standard approach is commonly used in population-
based studies to take into account other causes of death. The
Stata program strel (v1.2.7; http://csg.lshtm.ac.uk/tools-ana
lysis/strel-strel2/) was used to estimate relative survival (RS)
and corresponding 95% Confidence Intervals (95% CI); with
age and sex-specific background mortality rates being
obtained from national life tables (Cancer Research UK Can-
cer Survival Group, 2017, Patients still alive were censored at
time of last follow-up (25 March 2017). Outcomes for
patients managed with either chemotherapy or radiotherapy
were examined from the date first treatment was given.
Results
With a median diagnostic age of 74 years (range 35–96), 339
patients were newly diagnosed with MCL during the study
period; yielding a crude incidence rate of 09 per 100 000 per
year, and the European Standard 2013 age-standardised inci-
dence (Eurostat 2013) rate of 10 per 100 000 per year. Men
were almost three times more likely to be diagnosed with
MCL than women; the European Standard 2013 age-standar-
dized (Eurostat 2013) male/female sex-rate ratio being 295
(95% CI 230–378). No changes in these patterns were
detectable over the 11-year study period (2004–2015).
Around half of all patients died from their disease within
three years of diagnosis; the three-year overall and relative
survival estimates being 439% (384–492) and 507% (444–
567) respectively, and the corresponding one-year estimates
being 672% (618–719) and 709% (652–758). Full clinical
details were available for the 335 (99%) patients who were
treated within the UK National Health Service (NHS), and
their baseline demographic and clinical characteristics are
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shown in Table I, alongside estimates of survival. Median
survival from date of diagnosis was 24 years; the 55 patients
(164%) diagnosed with the particularly aggressive blastic
variant having worse outcomes than those with the com-
moner subtype (median survivals = 11 and 28 years respec-
tively). As expected, survival decreased with increasing age
and with a median survival of 04 years, the outlook for the
65 patients whose performance status ranged from 2 to 4
was particularly poor [adjusted hazard ratio (HR) = 326
(235–453)].
Patients with adverse clinical and/or biological prognostic
factors fared significantly less well than those without these
features; the best prognosis being seen in the small group of
17 patients with Stage I and II disease, where the median
survival was 86 years and the adjusted HR was 036 (017–
075). With the exception of the WBC count, all blood and
tumour markers (haemoglobin (Hb), b2-microglobulin
(b2 m) and LDH) were strongly associated with survival;
each 10 unit (g/l) increase in Hb improving survival by 13%
(HR = 087; 082–093) and each one unit (mg/l) increase in
b2 m, decreasing survival by 14% (HR = 114; 107–121). Of
the 90% of patients whose LDH was measured, 47% had ele-
vated levels and these patients had poorer survival compared
to those with normal results (adjusted HR 166; 123–223).
The simplified MIPI score was calculated from its compo-
nents; the 49% of patients who were categorised as high risk
had a median survival of 14 years, whilst the 17% catego-
rized as low risk had a median survival of 51 years. The cell
proliferation marker Ki67 was measured in 168 (59%)
patients at diagnosis; 72 of these (367%) had a proliferation
of greater than 30% and a median survival of 11 years, com-
pared to those with a proliferation of less than 30%, who
had a median survival of 35 years.
Initial management
Initial management strategies are distributed by patients’
baseline characteristics including prognostic factors and mea-
sures of disease involvement in Table II. Whilst the majority
(69%) of patients were treated with chemotherapy, only 20
(9%) went on to receive a consolidation ASCT at this point
in their pathway, and these patients were, on average, the
youngest (573 years) and fittest [Eastern Cooperative Oncol-
ogy Group performance score (ECOG PS) 0/1]. A small
number of patients (n = 9), who were less likely to have
stage III/IV disease (625%), received radiotherapy only. The
63 (189%) patients managed initially by W&W were the
least likely to have B-symptoms (127%), and were also less
likely to express high levels of Ki67 (16% ≥30%) and more
likely to present with blood involvement (603%). Forty-five
(714%) of the W&W patients showed disease progression
during the study period (median time to progres-
sion = 324 days); 39 of these were subsequently treated with
chemotherapy and two with radiotherapy. The 18 patients
who remained on W&W during the follow-up period were
more likely to have blood involvement. These patients had a
very favourable outcome with a 5-year overall survival (OS)
of 81% (95% CI: 506–935) and relative survival (RS), which
takes into account deaths occurring in people of the same
age in the population as a whole, of 85% (476–964) (Fig-
ure S1). Thirty-two patients were treated with a palliative
approach from the outset; these patients tended to be older
(median age 823 years) and less fit (ECOG PS>1, 687%).
First-line therapy
In total, 281 patients were treated either immediately after
diagnosis (n = 240) or after an initial period of W&W
(n = 41); 270 with chemotherapy and 11 with radiotherapy
only (Table III). Outcomes among the 157 patients treated
with chemotherapy and rituximab were better than those of
the 113 treated with chemotherapy alone (v2 = 95,
P = 0002): the respective 1-year and 3-year OS estimates
being 722% (95% CI: 644–785) and 503% (420–581) for
those who received rituximab and 646% (550–727) and
291% (211–376) for those who did not (survival curves are
presented in Figure S2). Patients who received rituximab
were, however, slightly younger (median age 702 years) than
those who did not (median 748 years); nonetheless the RS
estimates, which take into account deaths occurring in peo-
ple of the same age in the population as a whole, are broadly
similar (Table III).
The 22 patients who received a consolidation ASCT (two
of whom were originally on W&W) were, on average,
younger than those in the other groups (median age
574 years) and had the best outcomes; the 1-year OS being
955% (721–994) and the 3-year 855% (614–951), the
survival curve is presented in Figure S3 (v2 = 143,
P = 00001). Only 23 (85%) patients were enrolled in a clin-
ical trial; recruiting between 2002 and 2010, this trial exam-
ined the addition of rituximab to fludarabine and
cyclophosphamide (FC) (Rule et al, 2016). As might be
expected, these patients had a younger median age
(675 years) than the chemotherapy group as a whole
(708 years).
The use of rituximab immunochemotherapy increased
markedly from around 30% in 2004/2005 to 864% in 2015,
and this was accompanied by notable changes in regimen
(Fig 1A). In 2004–2006, for example, patients predominantly
received FC, FCR (fludarabine, cyclophosphamide, ritux-
imab) or chlorambucil. From 2007 there was an increase in
the use of CHOP-R (cyclophosphamide, doxorubicin, vin-
cristine, prednisolone, rituximab), and from 2008, younger
fitter patients began to be treated with regimens containing
high-dose cytarabine, sometimes alongside ASCT. Ben-
damustine was introduced in 2012, and by 2014/2015 this
drug accounted for around a third of all first-line therapy,
with fludarabine-based regimens no longer being used.
Among treated patients, survival improved over the
11-year study period, yielding a year-on-year age-adjusted
Impact of novel therapies for mantle cell lymphoma
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HR of 095% (95% CI: 090–099), and 3-year RSs of 433%
(352–511) and 578% (448–687) respectively for the peri-
ods 2004-2011 and 2012–2015. The overall survival curves
for these two time-periods diverge a year after starting
treatment (Fig 1B), with median survival increasing from
20 years among the 182 patients treated 2004–2011 to
35 years among the 99 treated 2012–2015 (v2 = 45,
P = 003). Importantly, rituximab maintenance therapy was
Table I. Median survival times and hazard ratios (95% Confidence Intervals), distributed by baseline characteristics; HMRN patients diagnosed
between September 2004 and August 2015 and followed-up until March 2017.
Number (%)
Median survival
(years) (95% CI) Hazard ratio (95% CI) Adjusted† Hazard Ratio (95% CI)
Total 335 (100) 2.4 (1.8–2.9)
Diagnosis
Common type 280 (83.6) 2.8 (1.9–3.4) 1 1
Blastic variant 55 (16.4) 1.1 (0.5–2.2) 1.67 (1.21–2.32) 1.96 (1.40–2.75)
Sex
Males 223 (66.6) 2.1 (1.5–2.8) 1 1
Females 112 (33.4) 2.7 (1.9–3.5) 1.06 (0.81–1.39) 0.86 (0.65–1.13)
Age at diagnosis (years)
Median (range) 74.0 (34.6–96.3)
<70 years 132 (39.4) 3.9 (2.8–5.9) 0.48 (0.36–0.63) 0.41 (0.31–0.56)
≥70 years 203 (60.6) 1.6 (1.2–2.1) 1 1
Performance status (ECOG)
0–1 266 (79.4) 3.3 (2.5–3.9) 1 1
2–4 65 (19.4) 0.4 (0.1–0.5) 3.84 (2.83–5.19) 3.26 (2.35–4.53)
Not known 4 – – –
B symptoms
No 206 (61.5) 2.9 (2.1–3.8) 1 1
Yes 129 (38.5) 1.6 (0.8–2.4) 1.31 (1.01–1.70) 1.18 (0.89–1.56)
Stage
I–II 17 (6.0) 8.6 (3.2–NR) 0.43 (0.21–0.88) 0.36 (0.17–0.75)
III–IV 264 (94.0) 2.2 (1.8–2.7) 1 1
Not fully staged* 54 1.5 (0.5–3.1) 1.35 (0.96–1.92) 0.67 (0.45–1.00)
Haemoglobin (g/l)
Mean (SD) 118 (23) – 0.88 (0.84–0.93)‡ 0.87 (0.82–0.93)‡
b2-microglobulin (mg/l)
Mean (SD) 5.3 (3.4) – 1.20 (1.14–1.26)§ 1.14 (1.07–1.21)§
White blood cell count(109/l)
Median (p25–p75) 8.8 (6.4–15.7) – 1.00 (1.00–1.00)§ 1.00 (1.00–1.00)§
Lactate dehydrogenase
Normal 161 (53.3) 3.9 (2.8–5.1) 1 1
Raised 141 (46.6) 1.5 (0.9–2.1) 1.81 (1.38–2.38) 1.66 (1.23–2.23)
Unknown 33 0.4 (0.1–1.4) 2.58 (1.67–3.99) 2.51 (1.58–4.00)
Simplified MIPI risk group
Low 50 (16.7) 5.1 (3.7–9.1) 0.40 (0.26–0.62) –
Intermediate 103 (34.3) 3.3 (2.4–4.2) 0.61 (0.45–0.83) –
High 147 (49.0) 1.4 (0.9–2.1) 1 –
Not known 35 0.5 (0.1–1.4) 1.36 (0.89–2.08) –
Ki67 index (%)
<30 124 (63.3) 3.5 (2.7–4.6) 1 1
≥30 72 (36.7) 1.1 (0.8–1.9) 1.81 (1.30–2.54) 1.72 (1.05–2.80)
Not tested 139 1.8 (1.3–3.2) 1.21 (0.90–1.62) 1.00 (0.73–1.37)
95% CI: 95% confidence interval; ECOG: Eastern Cooperative Oncology Group; HMRN: Haematological Malignancy Research Network; MIPI:
Mantle cell lymphoma International Prognostic Index; NR: not reached; p25–p75: 25th percentile-75th percentile; SD: standard deviation.
*36 computed tomography/positron emission tomography (CT/PET) staging scan only, 2 bone marrow assessment only, 16 neither bone marrow
assessment nor CT/PET scan.
†Adjusted for all other variables.
‡Hazard ratio for 10-unit (g/l) increase.
§Hazard ratio for one-unit increase.
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Table II. Initial management distributed by baseline characteristics; HMRN patients diagnosed between September 2004 and August 2015.
Total
Chemotherapy
Radiotherapy only
W&W
Palliative/Supportive carePatients
ASCT (% of those initially treated
with chemotherapy)
Patients
Disease progression (%
of those initially
managed by W&W)
No Yes No Yes
Number of patients (%) 335 (100) 231 (69.0) 211 (62.9) 20 (9.1) 9 (2.7) 63 (18.9) 18 (28.6) 45 (71.4) 32 (9.6)
Male (%) 223 (66.6) 161 (69.7) 147 (70.0) 13 (65.0) 3 (33.3) 37 (58.7) 19 (42.2) 26 (57.8) 22 (68.8)
Median age, years 74.0 (34.6–96.3) 74.4 73.9 (42.8–92.3) 57.3 (34.6–65.9) 78.0 (69.6–87.1) 74.8 (46.3–95.9) 74.4 75.4 82.3 (39.4–96.3)
High MIPI Score* 147 (49.0) 97 (44.9) 92 (46.9) 5 (25.0) 2 (25.0) 32 (53.3) 10 (58.8) 22 (51.2) 16 (100.0)
ECOG PS 0/1 (%) 266 (79.4) 190 (82.3) 169 (80.5) 20 (100) 8 (88.9) 58 (93.5) 16 (94.1) 42 (93.3) 10 (31.3)
B-symptoms (%) 129 (38.5) 107 (46.3) 101 (48.1) 6 (30.0) 1 (11.1) 8 (12.7) 3 (16.7) 5 (11.1) 13 (40.6)
Stage III/IV* (%) 264 (94.0) 197 (94.3) 179 (94.2) 18 (94.7) 5 (62.5) 43 (95.6) 12 (85.7) 31 (100.0) 19 (100.0)
Ki67 index ≥30%* (%) 72 (36.7) 57 (37.3) 54 (38.6) 3 (25.0) 3 (42.9) 4 (16.0) 0 4 (18.2) 8 (72.7)
Disease Involvement*
Nodal (%) 274 (81.8) 207 (92.4) 191 (93.2) 16 (84.2) 7 (100) 37 (66.1) 6 (37.5) 31 (77.5) 23 (92.0)
Spleen (%) 171 (53.8) 132 (58.1) 121 (58.7) 10 (50.0) 2 (28.6) 22 (37.3) 4 (25.0) 18 (42.9) 15 (60.0)
Extranodal (%) 288 (92.0) 202 (91.8) 183 (91.5) 19 (95.0) 4 (50.0) 58 (96.7) 18 (100) 40 (95.2) 24 (96.0)
Blood (%) 117 (35.8) 63 (27.6) 56 (26.9) 7 (36.8) 1 (14.3) 38 (60.3) 17 (94.4) 21 (46.7) 15 (51.7)
Marrow (%) 224 (83.3) 164 (82.4) 148 (82.2) 16 (84.2) 3 (37.5) 40 (90.9) 11 (84.6) 26 (83.9) 17 (94.4)
ASCT: Autologous stem cell transplantation; ECOG PS: Eastern Cooperative Oncology Group performance score; HMRN: Haematological Malignancy Research Network; MIPI: Simplified mantle cell
lymphoma International Prognostic Index; W&W: watch and wait. The italics indicate that the 211+20 are subsets of the 231 patients treated with chemotherapy. Likewise, the 18 + 45 are subsets
of the 63 who were on W&W.
*Percentages calculated excluding subjects who have not been staged or tested.
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Table III. First-line therapy; median age at treatment onset, overall survival (OS) and relative survival (RS): HMRN patients diagnosed between September 2004 and August 2015 and followed-up
until March 2017.
Number (%) Median age (years)
1-year survival (%) 3-year survival (%)
Overall (95% CI) Relative (95% CI) Overall (95% CI) Relative (95% CI)
Total patients 281 (100)* 72.2 69.4 (63.6–74.5) 72.7 (66.6–77.9) 41.8 (35.9–47.7) 47.9 (41.1–54.5)
Chemotherapy total 270 (96.1) 71.8 69.0 (63.1–74.2) 72.3 (66.0–77.6) 41.2 (35.1–47.1) 47.1 (40.1–53.7)
Chemotherapy without rituximab 113 (40.2) 74.8 64.6 (55.0–72.7) 68.2 (57.8–76.5) 29.1 (21.1–37.6) 34.4 (24.8–44.2)
Chemotherapy with rituximab 157 (56.0) 70.2 72.2 (64.4–78.5) 75.1 (66.9–81.5) 50.3 (42.0–58.1) 56.0 (46.6–64.3)
Chemotherapy + ASCT 22 (8.1) 57.4 95.5 (72.1–99.4) 96.3 (65.8–99.7) 85.5 (61.4–95.1) 87.3 (60.4–96.4)
Trial participants† 23 (8.5) 67.5 87.2 (65.4–95.7) 90.5 (63.5–97.9) 46.8 (25.8–65.4) 51.4 (27.7–70.8)
Radiotherapy only 11 (3.9) 76.0 80.2 (41.4–94.6) 83.9 (37.2–96.9) 59.0 (23.6–82.5) 75.5 (15.6–95.8)
Chemotherapy regimen (% of chemotherapy total, n = 270)
FC-based: 99 (35.2) 70.3 74.4 (64.6-81.9) 76.7 (66.4-84.3) 39.5 (29.9-49.0) 44.2 (33.3-54.6)
FC 54 70.5 71.7 (57.6–81.9) 74.0 (59.1–84.2) 30.2 (18.6–42.6) 34.4 (21.0–48.1)
FC-R 45 71.2 77.6 (62.4–87.2) 79.9 (63.7–89.4) 50.7 (35.4–64.2) 55.9 (38.6 – 70.0)
CHOP +/ rituximab‡ 53 (19.6) 74.1 59.3 (44.9–71.1) 61.6 (46.4–73.7) 38.5 (25.1–51.7) 43.0 (27.8–57.3)
Chlorambucil +/ rituximab 47 (17.4) 82.6 54.9 (39.9–67.6) 59.2 (42.6–72.5) 20.8 (10.6–33.3) 26.4 (13.2–41.6)
High dose cytarabine§ +/ rituximab¶ 45 (16.7) 58.1 91.1 (77.9–96.5) 92.1 (77.8–97.4) 76.8 (61.0–86.8) 78.7 (62.0–88.6)
Bendamustine +/ rituximab 18 (6.7) 80.4 59.6 (33.7–78.1) 65.2 (35.1–83.9) – –
CVP +/ rituximab 8 (3.0) 75.9 45.4 (12.2–74.3) 46.7 (12.2–75.9) 33.8 (7.1–64.1) 35.1 (7.2–65.9)
Year of treatment
2004–2011 182 (64.8) 71.9 68.6 (61.3–74.8) 71.7 (63.9 – 78.0) 37.9 (30.8–44.8) 43.3 (35.2–51.1)
2012–2015 99 (35.2) 73.7 70.9 (60.8–78.9) 74.7 (63.7–82.7) 50.1 (39.1–60.1) 57.8 (44.8–68.7)
95% CI: 95% confidence interval; ASCT: autologous stem cell transplantation; CHOP: cyclophosphamide, doxorubicin, vincristine, prednisolone. CVP: cyclophosphamide, vincristine, prednisolone;
DHAP: dexamethasone, cytarabine, cisplatin; FC: fludarabine, cyclophosphamide; FC-R: fludarabine, cyclophosphamide, rituximab; HyperCVAD: hyperfractionated cyclophosphamide, vincristine,
doxorubicin, and dexamethasone combined with cytarabine and methotrexate; HyperCVAD/MAG: HyperCVAD + high dose methotrexate, high dose cytarabine and granulocyte colony-stimulating
factor.
*240 were initially treated by either chemotherapy or radiotherapy and 41 patients were treated after an initial period of watch and wait.
†International Standard Randomized Controlled Trial Number (ISRCTN)81133184 (Rule et al, 2016).
‡1 patient also had an ASCT.
§High dose cytarabine regimens included: CHOP/DHAP, DHAP, HyperCVAD, HyperCVAD/MAG.
¶21 patients also had an ASCT.
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also introduced during the study period, the first patient
receiving it in 2010 and the remainder (n = 35) in 2012 or
later; 30 of these 36 patients survived for 3 years or more
after starting first-line therapy.
As expected, outcome varied considerably by regimen
(Table III, Fig 2A). For example, 1-year and 3-year OS for
patients treated with high dose cytarabine (+/rituximab)
were 911% (779–965) and 768% (610–868) respectively,
whereas those for chlorambucil (+/rituximab) were 549%
(399–676) and 208% (106–333). Patients treated inten-
sively with cytarabine were, however, significantly younger
(median age 581 years) than those receiving chlorambucil
(median age 826 years); hence the differences, although still
statistically significant, are less pronounced when age was
accounted for (RS estimates in Table III; age-adjusted curves
in Fig 2B).
Relapse/Refractory (RR) treatment
One hundred and forty (418%) of the 335 patients who
received first-line treatment went on to have second-line ther-
apy, 45 due to refractory disease and 95 who initially
responded then relapsed (median time to relapse 13 years,
range 002–60 years). The majority of these patients received
second-line chemotherapy (127/140), with the remainder hav-
ing radiotherapy (Table IV). In turn, 55 (393%) of the 140
patients who received second-line treatment went on to receive
third-line therapy and so on. Overall, 233 RR treatment lines
were administered (median 2 lines per patient, range 1–5) with
diminishing returns (Figure S4): median survival decreasing
from 08 years following second-line (n = 140), 06 years fol-
lowing third-line (n = 55), 04 years following fourth-line
(n = 28) and 01 years following fifth-line (n = 8).
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Fig 1. (A) First Line Regimen by Year of Treatment. (B) Overall survival by time of first line treatment. CHOP: cyclophosphamide, doxorubicin,
vincristine, prednisolone; CVP: cyclophosphamide, vincristine, prednisolone; FC: fludarabine, cyclophosphamide; FC-R: fludarabine, cyclophos-
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Fig 2. (A) Overall Survival by First Line Chemotherapy. (B) Overall Survival by First Line Chemotherapy Adjusted by Age at Treatment. CHOP:
cyclophosphamide, doxorubicin, vincristine, prednisolone; FC: fludarabine, cyclophosphamide; FC-R: fludarabine, cyclophosphamide, rituximab.
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Table IV. Treatment for relapsed/refractory disease; median age at treatment onset, median survival and one-year overall survival (OS); HMRN patients diagnosed between September 2004 and
August 2015 and followed-up until March 2017.
Second Line§ All Refractory/Relapsed Treatment Lines
Patients (%)
Median
age (years)
Median
survival
(years)
1-year overall
survival (%)
(95% CI) Number (%)
Median
age (years)
Median
survival (years)
1-year overall
survival (%) (95% CI)
Total patients 140 (100) 72.6 0.8 45.5 (37.2–53.3) 233 (100) 72.4 0.7 39.2 (33.0–45.3)
Chemotherapy total: 127 (90.7) 71.2 0.8 44.8 (36.2–53.0) 205 (88.0) 72.0 0.7 39.9 (33.3–46.4)
without rituximab 64 (50.4) 76.9 0.7 41.9 (29.9–53.4) 104 (50.7) 74.1 0.5 31.6 (23.2–40.3)
with rituximab 63 (49.6) 68.8 1.0 47.7 (35.3–59.1) 101 (49.3) 69.3 1.0 48.5 (38.6–57.7)
Radiotherapy only 13 (9.3) 75.8 1.3 46.4 (30–61.3) 28 (12.0) 77.5 0.4 33.9 (17.5–51)
Chemotherapy regimen*
FC-based 21 (16.5) 70.7 0.8 41.8 (21.5–60.9) 30 (14.6) 73.9 0.8 44.7 (26.8-61.0)
FC 7 83.7 0.3 24.4 (3.4–55.6) 10 81.4 0.4 28.0 (6.9–54.5)
FC-R 14 68.2 0.8 50.4 (23.7–72.1) 20 68.2 1.0 53.4 (29.9–72.1)
CHOP(+/R) 27 (21.3) 72.0 1.2 53.3 (33.8–69.4) 37 (18.0) 72.8 0.8 44.8 (29.2–59.3)
Chlorambucil (+/R) 13 (10.2) 83.9 0.4 34.9 (12.2–59.1) 19 (9.3) 83.9 0.6 38.4 (17.8–58.9)
High-dose cytarabine† (+/R) 23 (18.1) 62.2 1.1 49.8 (28.3–67.9) 38 (18.5) 62.5 0.5 31.7 (18–46.3)
Bendamustine (+/R) 12 (9.4) 70.8 0.6 31.6 (10–56.2) 20 (9.8) 68.6 1.0 52.9 (29.4–71.8)
Ibrutinib 16 (12.6) 79.6 1.1 61.5 (33.9–80.4) 25 (12.2) 77.5 1.1 60.6 (39.5–76.4)
Other‡ 15 (11.8) 77.5 0.7 29.1 (10.8–50.5) 36 (17.6) 75.4 0.2 19.3 (9.2–32.1)
Year of treatment
2005–2011 90 (64.3) 72.4 0.7 38.9 (29.1–48.5) 140 (60.1) 71.9 0.5 32.1 (24.8–39.6)
2012–2016 50 (25.7) 73.8 1.4 57.5 (42.9–69.7) 93 (39.9) 73.7 1.0 50.5 (39.9–60.1)
95% CI: 95% confidence interval; ASCT: autologous stem cell transplantation; CHOP: cyclophosphamide, doxorubicin, vincristine, prednisolone. CVP: cyclophosphamide, vincristine, prednisolone;
DHAP: dexamethasone, cytarabine, cisplatin; FC: fludarabine, cyclophosphamide; FC-R: fludarabine, cyclophosphamide, rituximab; HyperCVAD: hyperfractionated cyclophosphamide, vincristine,
doxorubicin, and dexamethasone combined with cytarabine and methotrexate; HyperCVAD/MAG: HyperCVAD + high dose methotrexate, high dose cytarabine and granulocyte colony-stimulating
factor.
*Percentage of the total treated with chemotherapy at second line (n = 127) or all refractory/relapsed line (n = 205).
†High dose cytarabine regimens included: CHOP/DHAP, DHAP, HyperCVAD, HyperCVAD/MAG.
‡Included: CVP (+/rituximab) n = 6, single agent rituximab n = 7, bortezomib n = 4, etoposide n = 4, CHOP/bortezomib n = 2, thalidomide (n = 3), lenalidomide (n = 3), single agent fludara-
bine n = 3, methotrexate (it)/rituximab (n = 1), vincristine (n = 1), ofatumumab (n = 1).
§One patient received an allograft and two an autologous stem cell transplant.
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Approximately half of the patients treated for RR MCL
received rituximab immunochemotherapy, but the impact
was less marked than that observed at first-line (Table III);
the 1-years OS at second-line was 477% with rituximab
and 419% without rituximab and the corresponding fig-
ures for all lines combined were 485% and 316% respec-
tively (Table IV). The most common RR regimens
contained high-dose cytarabine (185%) followed by
CHOP-R (18%) and, as with first-line treatment, marked
changes were evident over the course of the 11-year study
period (Fig 3A). However, in contrast to first-line therapy
(Fig 1A), the proportion of RR regimens delivered with
rituximab showed no consistent trend over the study per-
iod (Fig 3A).
From 2012 onwards, the majority of patients with
relapsed or refractory disease were treated with either ben-
damustine or ibrutinib, prior to this there was no domi-
nant standard of care (Fig 3A). As with first-line therapy,
the marked changes over time in RR regimen appear to
have had a positive impact on outcome, as is evident in
Fig 3B (v2 = 68, P = 0009); 1-year OS increasing from
321% (248–396) in 2005–2011, to 505% (399–601) in
2012-2016 (Table IV). Despite the fact that ibrutinib-trea-
ted patients were older than most of the other groups
(median age 775 years) they had the best outcomes, with
a 1-year OS of 606% (395-764) (Table IV). Although the
numbers were small, stratification by age showed that the
survival improvements were most marked in older patients.
One-year OS among patients aged over 70 years with
RR disease, for example, increased from 284% (95% CI:
191–384) for those treated 2005–2011 to 530% (95% CI:
388–654) in those treated 2012–2016, the corresponding
estimates for those under 70 years were 362% (95% CI:
252–473) and 470% (95% CI: 310–615) respectively.
Discussion
Covering the full spectrum of MCL diagnoses, our contem-
porary real-world data illustrate the underlying heterogeneity
of the disease and its treatment. With a median diagnostic
age of 740 years, our patient population is, on average, 2–
5 years older than other published series (Herrmann et al,
2009; Abrahamsson et al, 2011, 2014; Epperla et al, 2017;
Vergote et al, 2017). This most likely reflects the fact that all
patients are identified at the point of diagnosis via a cen-
tralised diagnostic laboratory rather than retrospectively from
medical records, thereby ensuring all patients are captured
regardless of treatment intent; including those managed pal-
liatively from the outset. This method of ascertainment also
provides timely access to new diagnostic/prognostic measures
as they are introduced into clinical practice. For example,
our analyses provides the first population-based data on the
cell proliferation marker Ki67, revealing that around two-
thirds of MCL patients initially fall into the <30% category,
and confirming its prognostic role alone, as well as in combi-
nation with the MIPI score (Figure S5) (Klapper et al, 2009;
Hoster et al, 2016). With the exception of WBC count, all
components of the MIPI predicted OS in the general patient
population. The lack of association seen with WBC count
may be explained by the fact the MIPI was derived using
clinical trial data from cases with advanced disease (Hoster
et al, 2008), thus excluding patients with MCL where a high
WBC count may confer a prognostic benefit. Indeed, this
was confirmed when the analyses were repeated separately by
disease management; as WBC increased, survival increased,
in those managed by W&W, whereas it fell in those treated
with chemotherapy (Figure S6).
Although MCL continues to have a poor prognosis and
remains one of the most challenging lymphomas to treat,
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Fig 3. (A) Relapsed/Refractory Treatment by Year of Treatment. (B) Overall Survival by Year of Treatment, CHOP: cyclophosphamide, doxoru-
bicin, vincristine, prednisolone; FC: fludarabine, cyclophosphamide; FC-R: fludarabine, cyclophosphamide, rituximab; R: rituximab.
Impact of novel therapies for mantle cell lymphoma
ª 2018 The Authors. British Journal of Haematology published by
John Wiley & Sons Ltd. 9
Table V. First line chemotherapy by baseline characteristic
Total
Regimen
FC FC-R
CHOP +/
Rituximab
Chlorambucil +/
Rituximab
High dose cytarabine †
+/ Rituximab
Bendamustine +/
Rituximab CVP +/ Rituximab
Number of patients (%) 231 49 (21.2) 37 (16.0) 48 (20.8) 38 (16.5) 38 (16.5) 14 (6.1) 7 (3.0)
Ritxumab (%) 136 (58.9) – 37 (100.0) 46 (95.8) 4 (10.5) 31 (81.6) 12 (85.7) 6 (85.7)
Male (%) 161 (69.7) 35 (71.4) 26 (70.3) 34 (70.8) 22 (57.9) 25 (65.8) 14 (100.0) 5 (71.4)
Median age - years 74.4 69.9 71.2 74.3 81.4 57.5 81.4 76.6
High MIPI Score*(%) 97 (44.9) 19 (40.4) 11 (30.6) 25 (56.8) 21 (60.0) 8 (24.2) 9 (64.3) 4 (57.1)
ECOG PS 0/11 (%) 190 (82.3) 39 (81.3) 34 (91.9) 38 (79.2) 26 (68.4) 38 (100.0) 11 (78.6) 4 (57.1)
B-symptoms (%) 107 (46.3) 23 (46.9) 22 (59.5) 23 (47.9) 16 (42.1) 12 (31.6) 7 (50.0) 4 (57.1)
Stage III/IV* (%) 196 (93.8) 39 (88.6) 33 (97.1) 43 (95.6) 30 (90.9) 34 (94.4) 11 (100) 6 (100)
Blastic variant* (%) 44 (19.0) 9 (18.4) 5 (13.5) 15 (31.3) 4 (10.5) 7 (18.4) 1 (7.1) 3 (42.9)
Ki673 index (≥30%)* (%) 57 (37.3) 11 (28.9) 10 (40.0) 16 (53.3) 6 (26.1) 8 (29.6) 3 (42.9) 3 (100.0)
Disease involvement*
Nodal (%) 207 (92.4) 43 (91.5) 35 (100.0) 43 (89.6) 31 (86.1) 35 (94.6) 14 (100.0) 6 (85.7)
Spleen (%) 132 (58.1) 25 (52.1) 20 (57.1) 29 (60.4) 21 (56.8) 22 (57.9) 9 (64.3) 6 (85.7)
Extranodal (%) 202 (91.8) 40 (87.0) 32 (94.1) 40 (87.0) 34 (94.4) 37 (97.4) 13 (92.9) 6 (100)
Blood (%) 63 (27.6) 10 (20.4) 7 (20.0) 14 (29.2) 11 (28.9) 9 (24.3) 9 (64.3) 3 (42.9)
Marrow (%) 161 (80.9) 32 (76.2) 28 (80.0) 34 (81.0) 24 (80.0) 31 (86.1) 7 (87.5) 5 (83.3)
Median Year of Diagnosis 2010 2008 2009 2012 2009 2012 2014 2012
CHOP: cyclophosphamide, doxorubicin, vincristine, prednisolone. CVP: cyclophosphamide, vincristine, prednisolone; DHAP: dexamethasone, cytarabine, cisplatin; ECOG PS: Eastern Cooperative
Oncology Group performance score; FC: fludarabine, cyclophosphamide; FC-R: fludarabine, cyclophosphamide, rituximab; HyperCVAD: hyperfractionated cyclophosphamide, vincristine, doxoru-
bicin, and dexamethasone combined with cytarabine and methotrexate; HyperCVAD/MAG: HyperCVAD + high dose methotrexate, high dose cytarabine and granulocyte colony-stimulating factor;
MIPI: Simplified mantle cell lymphoma International Prognostic Index.
*Percentages calculated excluding subjects who have not been staged or tested.
†High dose cytarabine regimens included: CHOP/DHAP, DHAP, HyperCVAD, HyperCVAD/MAG.
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our analyses confirm that the marked therapeutic changes
introduced in recent years appear to be having a favourable
impact on outcome in the general patient population; the
median survival increasing in our cohort from 20 years
among those who had their first treatment between 2004 and
2011 to 35 years among those treated between 2012 and
2015. Furthermore, significant improvements in outcome
were also detectable for RR disease, with the median survival
from initiation of second line treatment increasing from
8 months in 2004–2011 to 168 months in 2012-2015.
Importantly, however, within our cohort the benefits of ther-
apy for RR disease declined markedly with each treatment
episode, with patients receiving fifth-line therapy, on average,
surviving < 2 months.
The rarity of MCL, coupled with the range and evolving
complexity of the various treatment options, can make it chal-
lenging to identify the key drivers of survival changes observed
in the real-world setting. Confirming the findings of others
(Schulz et al, 2007; Leux et al, 2014), however, our data
clearly demonstrate the benefit of the addition of rituximab to
first-line chemotherapy in the general patient population; at
31 years the median survival of those who received rituximab
immunochemotherapy at first-line was twice that of those
who did not. Likewise, although patients who received ritux-
imab immunochemotherapy for RR disease fared better than
those who did not, its use did not increase during the study
period, and the survival improvements seen through 2012–
2015 are more likely due to the introduction of novel agents,
particularly bendamustine and ibrutinib. In this context, phase
II/III studies have demonstrated the effectiveness of ben-
damustine and ibrutinib, generally with less toxicity than that
associated with other intensive chemotherapy (Rummel et al,
2013, 2017; Dreyling et al, 2016; Wang et al, 2016). Encourag-
ingly, our population-based findings confirm that these novel
agents seem to be impacting particularly on the survival of
patients who may be less able to withstand intensive treat-
ment; the 1-year OS among patients over 70 years treated for
relapsed/refectory disease almost doubling, reaching 50% and
matching that of patients under 70 years of age.
With the patient groups that received either a consolida-
tion ASCT or rituximab maintenance therapy after first-line
chemotherapy both achieving 3-year overall survivals exceed-
ing 80%, our data also confirm the value of treatment post-
induction. Importantly, our real-world findings for ASCT are
similar to those reported in clinical trials; and a recent review
of the role of ASCT in the management of MCL confirmed
that this remains the standard of care for younger patients.
(Dreyling & Ferrero, 2016). The proportion of patients trans-
planted in our study was, however, relatively small as current
clinical guidelines only recommend ASCT for patients under
65 years (McKay et al, 2012; Dreyling et al, 2017) who are
deemed fit enough to undergo the procedure. In our popula-
tion, 34 of the 70 patients under 65 years were identified for
ASCT; of these 22 had the procedure, one patient refused,
and harvest attempts were unsuccessful for 10, a similar
failure rate to that reported by others (Kuittinen et al, 2004).
Indeed, the difficulty of achieving stem cell mobilisation in
MCL compared to other non-Hodgkin lymphomas has been
noted by others, particularly among those previously treated
with Hyper-CVAD (hyperfractionated cyclophosphamide,
vincristine, doxorubicin, and dexamethasone combined with
cytarabine and methotrexate) (Hill et al, 2011; Kurnaz &
Kaynar, 2015; Sawalha et al, 2018).
Whilst it is well recognised that indolent MCL exists and,
as with some other lymphomas, W&W in these cases is con-
sidered an acceptable management approach (Martin et al,
2009, 2017; Furtado & Rule, 2011), the clinical characteristics
of our W&W patients support the fact that there are two dis-
tinct variants of ‘indolent’ MCL, as described in the recent
revision of the 2016 WHO classification (Swerdlow et al,
2016; Leonard et al, 2017). The 18 patients whose disease did
not progress during the study period were less likely to have
nodal disease, but more likely to have blood involvement,
and these patients had far more favourable outcomes, with
5-year OS exceeding 80%.
Major strengths of our study include its large, well-defined
catchment population and world-class centralised diagnostics;
ensuring consistency of the diagnostic process as well as com-
pleteness of ascertainment. Accordingly, we are confident that
all new MCL diagnoses were captured, which may account for
the fact that our annual incidence rate [crude 09 per 100 000,
European Standard 2013 age-standardised (Eurostat 2013) 10
per 100 000] is more stable and slightly higher than that
reported for some other series (Andersen et al, 2002; Abra-
hamsson et al, 2011, 2014; Chandran et al, 2012; Leux et al,
2014). Likewise, the fact that our cohort has a slightly higher
average age and includes those treated with a palliative/sup-
portive approach (96%) may also help explain why our OS is
slightly lower than that reported in some other populations
(Andersen et al, 2002; Abrahamsson et al, 2011, 2014; Leux
et al, 2014). Another important factor, however, is the fact
that only 40% of our patients received rituximab
immunotherapy prior to 2011; this reflects national regulatory
policy as rituximab has not been approved for routine use in
the NHS (National Institute for Health and Care Excellence
[NICE] 2016) despite being recommended for use in national
guidelines in 2012 (McKay et al, 2012). This contrasts with
the situation in some other countries, with the Nordic Lym-
phoma Group, for example, reporting that 50% of patients
diagnosed 2000-2005 received first-line rituximab
immunochemotherapy, increasing to 77% by 2006-2011 and
the corresponding OS estimates being 51% and 61% respec-
tively (Abrahamsson et al, 2014).
The major weakness of our study, like those of many
others, is small numbers. Outcomes differed by regimen, but
due to the rarity of MCL the numbers of patients treated by
some agents was small. Furthermore, as this is an observa-
tional study it is difficult to compare the efficacy of different
regimens, as not only did the age profiles of the patients dif-
fer by therapy, but also the baseline characteristics. For
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example, for those treated immediately after diagnosis (i.e. not
after a period of W&W), differences were seen in the demo-
graphic, diagnostic and prognostic factors by type of induction
chemotherapy received (Table V). As expected, younger and
fitter patients received regimens containing high-dose cytara-
bine, whereas older patients were more likely to be treated
with either chlorambucil or bendamustine. Interestingly, R-
CHOP treated patients were more likely to be diagnosed with
the blastic variant (313% vs. 190%) and express higher levels
of Ki67 proliferation index (533% vs. 373%).
The development of novel agents has increased the ability
to treat MCL patients who previously were unable to tolerate
intensive treatments, and our findings show an improvement
in survival across a population with a disease that is chal-
lenging to treat. The study highlights the importance of util-
ising data from high-quality population-based registries to
monitor the impact of changes in treatment. This is espe-
cially relevant for rare diseases where it is challenging to con-
duct Phase 3 clinical trials (Martin, 2016), particularly in
conditions where the treatment landscape is changing
rapidly. We plan to continue monitoring the management
and outcome of MCL, and to assess the impact of novel
agents, including the introduction of immunomodulatory
agents, such as lenalidomide.
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